Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.75 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.70 |
| ▸ | HSD17B1 | P14061 | 8/20 | 0.69 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SCD | O00767 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27717411 | 0.86 | DYRK1A (0.73) | DYRK1ADYRK1BHSD17B1HSD17B2MAOA | |
| SCHEMBL10170616 | 0.86 | DYRK1A (1.00) | DYRK1ADYRK1BHSD17B1HSD17B2CYP3A4 | |
| SCHEMBL2764027 | 0.84 | DYRK1A (0.57) | DYRK1ADYRK1BHSD17B1CYP3A4CYP2C9 | |
| SCHEMBL29788 | 0.84 | HSD17B1 (0.82) | DYRK1ADYRK1BHSD17B1HSD17B2SCD | |
| SCHEMBL31024 | 0.83 | HSD17B1 (0.82) | DYRK1ADYRK1BHSD17B1HSD17B2CYP3A4 | |
| SCHEMBL11724806 | 0.83 | DYRK1A (1.00) | DYRK1ADYRK1BHSD17B1HSD17B2HSD17B10 | |
| SCHEMBL16554035 | 0.83 | HSD17B1 (0.76) | DYRK1ADYRK1BHSD17B1HSD17B2HSD17B10 | |
| SCHEMBL3708649 | 0.83 | RAB9A (0.76) | DYRK1ACYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL3787846 | 0.83 | DYRK1A (0.76) | DYRK1ACYP2C9CYP2C19 | |
| SCHEMBL14539566 | 0.82 | DYRK1A (0.72) | DYRK1ADYRK1BHSD17B1HSD17B2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110571-B2 | Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents | AVENTIS PHARMA S.A. (FR) | 2012-02-07 | — | — | US | disclosed |
| WO-2010066357-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
| CN-101273019-A | Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use especially as C-Met inhibitors | AVENTIS PHARMA SA (FR) | 2008-09-24 | — | — | CN | disclosed |
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-08-14 | — | — | US | disclosed |
| EP-1934187-A1 | NOVEL BENZIMIDAZOLE AND BENZOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | Aventis Pharma S.A. (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007036630-A1 | NOVEL BENZIMIDAZOLE AND BENZOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | MET, KIT, MERTK | DYRK1A 3467/4885DYRK1B 2511/4885HSD17B1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.